Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Lilly and Pfizer ... Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

Demand for weight loss drugs over the past couple of years has put Lilly's and Novo Nordisk's drugs on the U.S. Food and Drug ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...

Eli Lilly became the second drugmaker this week to sue the U.S. government for rejecting their proposed changes to a program ...

Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...